Rakovina Therapeutics Inc.
RKVTF
$0.10
$0.00-4.61%
OTC PK
| 03/31/2026 | 09/30/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | 239.66% | 247.69% | 247.69% | 172.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 154.27% | 161.25% | 161.25% | 98.06% |
| Operating Income | -- | -154.27% | -161.25% | -161.25% | -98.06% |
| Income Before Tax | -- | -146.07% | -150.00% | -150.00% | -94.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -146.07% | -150.00% | -150.00% | -94.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -146.07% | -150.00% | -150.00% | -94.13% |
| EBIT | -- | -154.27% | -161.25% | -161.25% | -98.06% |
| EBITDA | -- | -187.93% | -202.20% | -202.20% | -125.47% |
| EPS Basic | -- | -26.09% | -38.58% | -38.58% | -31.99% |
| Normalized Basic EPS | -- | 6.73% | -38.09% | -4.34% | 4.71% |
| EPS Diluted | -- | -24.97% | -52.53% | -34.92% | -26.10% |
| Normalized Diluted EPS | -- | 6.73% | -38.09% | -4.34% | 4.71% |
| Average Basic Shares Outstanding | -- | 103.61% | 74.60% | 74.60% | 43.55% |
| Average Diluted Shares Outstanding | -- | 103.61% | 74.60% | 74.60% | 43.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |